Related Experiment Video
Updated: May 9, 2026

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
Published on: July 24, 2021
Current and prospective treatments for multidrug-resistant gram-positive infections
Jeffrey M Rybak1, Katie E Barber, Michael J Rybak
1University of Kentucky HealthCare, Department of Pharmacy , 800 Rose Street Room H110, Lexington KY 40536 , USA.
Introduction:
Staphylococcus aureus and Enterococcus spp. are two of the most common organisms causing nosocomial infections today; and are consistently associated with high mortality rates (approximately 20 and 44%, respectively). Resistance among these pathogens to first line agents such as methicillin and vancomycin continues to rise while isolates with reduced susceptibility to newer agents including linezolid and daptomycin continue to emerge, representing a serious concern for clinicians.
Areas Covered:
Mechanisms of action and resistance as well as in vitro and clinical experience in the treatment of resistant staphylococci and enterococci with currently available agents are discussed. Additionally, novel combination regimens showing enhanced efficacy and available data pertaining to prospective therapies including solithromycin, tedizolid, dalbavancin and oritavancin will be covered.
Expert Opinion:
With an increase in organisms displaying reduced susceptibility to vancomycin and the associated treatment failures, the significance of alternative therapies such as daptomycin, linezolid, ceftaroline, and prospective anti-gram-positive agents is on the rise. As our understanding of antimicrobial pharmacokinetic-pharmacodynamics principles continues to evolve, the selection of highly effective agents and optimization of dosages may lead to improved patient outcomes and delay the development of resistance.
Insights
Emerging resistance to antibiotics like vancomycin in Staphylococcus aureus and Enterococcus spp. necessitates exploring alternative therapies. New agents and optimized dosing are crucial for treating these nosocomial infections and preventing further resistance.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Staphylococcus aureus and Enterococcus spp. are leading causes of nosocomial infections with high mortality rates.
- Increasing resistance to methicillin and vancomycin, and emerging resistance to linezolid and daptomycin, pose significant clinical challenges.
Purpose of the Study:
- To review current and novel therapeutic strategies for resistant Gram-positive bacterial infections.
- To discuss mechanisms of action, resistance, and clinical data for existing and emerging anti-infective agents.
Main Methods:
- Review of in vitro and clinical data on currently available agents for resistant staphylococci and enterococci.
- Discussion of novel combination regimens and prospective therapies like solithromycin, tedizolid, dalbavancin, and oritavancin.
Main Results:
- Limited effectiveness of first-line agents due to rising resistance.
- Emergence of reduced susceptibility to newer agents like linezolid and daptomycin.
Conclusions:
- Alternative therapies including daptomycin, linezolid, ceftaroline, and novel anti-Gram-positive agents are increasingly significant due to vancomycin resistance and treatment failures.
- Advancements in understanding antimicrobial pharmacokinetics-pharmacodynamics can improve patient outcomes and mitigate resistance development through optimized agent selection and dosing.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Acute Pyelonephritis II: Diagnostic Studies and Management
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Development of Antibiotic Resistance
Inhibitors of Gram-positive Cell Wall Synthesis
